| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/10/2013 | WO2013006658A1 Treatment of acetaminophen-induced liver damage by the administration of modulators of nitric oxide |
| 01/10/2013 | WO2013006505A1 Use of anti-cd83 agonist antibodies for treating autoimmune diseases |
| 01/10/2013 | WO2013006490A2 Antibodies that specifically bind to tim3 |
| 01/10/2013 | WO2013006449A2 Anti-properdin antibodies and uses thereof |
| 01/10/2013 | WO2013006437A1 Method for treating metabolic disorders |
| 01/10/2013 | WO2013006244A1 Bispecific monoclonal antibody therapeutics against west nile virus with improved cns penetration |
| 01/10/2013 | WO2013006055A1 A process for detergent-free production of outer membrane vesicles |
| 01/10/2013 | WO2013006050A1 Peptides inducing or enhancing an immune response against prostate-specific membrane protein (PSMA) |
| 01/10/2013 | WO2013006024A1 Diagnosis of entamoeba histolytica |
| 01/10/2013 | WO2013005873A1 An antibody inducing antigen-specific t cell tolerance and use thereof |
| 01/10/2013 | WO2013005839A1 Phosphorylated peptide, hard tissue and/or ectopic calcification inhibitor, antibody, and hard tissue and/or ectopic calcification promoter |
| 01/10/2013 | WO2013005649A1 Anti-human ccr6 antibody |
| 01/10/2013 | WO2013005194A2 Multispecific antibodies |
| 01/10/2013 | WO2013005164A2 Cancer antigen |
| 01/10/2013 | WO2013005108A1 Egfr targeted therapy |
| 01/10/2013 | WO2013004842A2 Antibody variants and uses thereof |
| 01/10/2013 | WO2013004806A1 Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof |
| 01/10/2013 | WO2013004708A1 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells |
| 01/10/2013 | WO2013004185A1 Broadly cross-reactive hiv-1-specific antibodies for prevention and treatment of hiv |
| 01/10/2013 | WO2013004076A1 Agr2 blocking antibody and use thereof |
| 01/10/2013 | WO2013004020A1 Pseudomonas aeruginosa (pa-msha) strain igy and preparation method and use thereof |
| 01/10/2013 | WO2013003904A1 Recombinant low virulence bovine herpesvirus 1 (bohv-1) vaccine vectors |
| 01/10/2013 | WO2013003895A1 Combination therapy |
| 01/10/2013 | WO2012158818A3 Multi-specific fab fusion proteins and methods of use |
| 01/10/2013 | WO2012149416A3 Human myeloid derived suppressor cell cancer markers |
| 01/10/2013 | WO2012149160A3 Viruses modified with unnatural moieties and methods of use thereof |
| 01/10/2013 | WO2012138102A3 Dlk1-specific human antibodies and pharmaceutical composition containing same |
| 01/10/2013 | WO2012138100A3 Activin receptor type ii b inhibitors comprising dlk1 extracellular water-soluble domain |
| 01/10/2013 | WO2012097313A3 Therapeutic antibodies against ror-1 protein and methods for use of same |
| 01/10/2013 | US20130012922 Compositions and methods for the treatment of cancer |
| 01/10/2013 | US20130012916 Delivery of immunoglobulin variable domains and constructs thereof |
| 01/10/2013 | US20130011861 Modulators of p-selectin glycoprotein ligand 1 |
| 01/10/2013 | US20130011443 Human respiratory syncytial virus vaccine |
| 01/10/2013 | US20130011438 Means And Methods For Active Cellular Immunotherapy Of Cancer By Using Tumor Cells Killed By High Hydrostatic Pressure and Dendritic Cells |
| 01/10/2013 | US20130011437 Immune compositions for treating H. pylori infection |
| 01/10/2013 | US20130011436 Methods and Compositions Containing Fc Fusion Proteins for Enhancing Immune Responses |
| 01/10/2013 | US20130011435 Composition for treating hbv infection |
| 01/10/2013 | US20130011434 Adjuvant diluents for live vaccines for pig diseases |
| 01/10/2013 | US20130011433 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4 |
| 01/10/2013 | US20130011432 Disrupted adenovirus-based vaccine against drugs of abuse |
| 01/10/2013 | US20130011431 Composition Comprising the Amyloid Beta 1-6 Peptide Coupled to a Virus-Like Particle and an Adjuvant |
| 01/10/2013 | US20130011430 HUMAN CHORIONIC GONADOTROPIN (hCG) BASED VACCINE FOR PREVENTION AND TREATMENT OF CANCER |
| 01/10/2013 | US20130011429 Immunogenic composition |
| 01/10/2013 | US20130011428 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| 01/10/2013 | US20130011427 Flavivirus species-specific peptide tags for vaccine and diagnostic use |
| 01/10/2013 | US20130011426 Recombinant Vaccines and Use Thereof |
| 01/10/2013 | US20130011425 Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
| 01/10/2013 | US20130011424 Polyepitope constructs and methods for their preparation and use |
| 01/10/2013 | US20130011422 Tumor Antigens for the Prevention and/or Treatment of Cancer |
| 01/10/2013 | US20130011421 Triterpene saponins, methods of synthesis, and uses thereof |
| 01/10/2013 | US20130011420 Antisense antiviral compounds and methods for treating a filovirus infection |
| 01/10/2013 | US20130011419 Cross-linkers and their uses |
| 01/10/2013 | US20130011418 Antibody-Drug Conjugates |
| 01/10/2013 | US20130011417 Colchicine derivatives or pharmaceutically acceptable salts thereof, method for preparing said derivatives, and pharmaceutical composition comprising said derivatives |
| 01/10/2013 | US20130011416 Injectable solution containing therapeutic agent for osteoarthritis |
| 01/10/2013 | US20130011415 Milk derived antigen specific antibodies for inducing an adaptive immune response, methods of preparation and uses thereof |
| 01/10/2013 | US20130011414 Broadly cross-reactive hiv-1-specific antibodies for prevention and treatment of hiv |
| 01/10/2013 | US20130011413 Method and Pharmaceutical Composition for Treatment of Intestinal Disease |
| 01/10/2013 | US20130011412 Antibodies to lymphotoxin-alpha |
| 01/10/2013 | US20130011411 Methods and compositions for the diagnosis, prognosis, and treatment of cancer |
| 01/10/2013 | US20130011410 Egg White Antibodies for Prevention and Treatment of Specific Localized Intestinal Infections and Diseases Associated with a Pathogenic Organism or Molecule |
| 01/10/2013 | US20130011409 Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1 |
| 01/10/2013 | US20130011408 Epidermal Growth Factor Receptor (EGFR) Protein SRM Assay |
| 01/10/2013 | US20130011407 Pharmaceutical composition for treatment or prevention of osteoarthritis, and method of production therefor |
| 01/10/2013 | US20130011406 Anti-kit antibodies and uses thereof |
| 01/10/2013 | US20130011405 Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| 01/10/2013 | US20130011404 Methods and Compositions for Regulating Musashi Function |
| 01/10/2013 | US20130011403 Klebsiella antigens |
| 01/10/2013 | US20130011402 Compositions and methods for the diagnosis and treatment of tumor |
| 01/10/2013 | US20130011401 Soluble proteins for use as therapeutics |
| 01/10/2013 | US20130011400 Methods For Inducing Autolysis In Infectious Bacteria |
| 01/10/2013 | US20130011399 WAP Domain Fusion Polypeptides and Methods of Use Thereof |
| 01/10/2013 | US20130011398 Serpin Fusion Polypeptides and Methods of Use Thereof |
| 01/10/2013 | US20130011397 Transforming growth factor-beta (TGF-beta) antagonists for use in treating pain |
| 01/10/2013 | US20130011396 Treatment protocol |
| 01/10/2013 | US20130011395 Methods and compositions for treating autoimmune diseases or conditions |
| 01/10/2013 | US20130011394 Complexes comprising mhc class i fusion polypeptides and antigen-specific antibodies and methods of use |
| 01/10/2013 | US20130011393 Bad pathway gene signature |
| 01/10/2013 | US20130011392 Method for assessing the ability of a patient to respond to or be safely treated by a nucleoside analog based-chemotherapy |
| 01/10/2013 | US20130011391 Anti-psgl-1 antibodies and uses thereof |
| 01/10/2013 | US20130011390 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 01/10/2013 | US20130011389 Compositions and methods for treating coagulation related disorders |
| 01/10/2013 | US20130011388 Intravenous immunoglobulin composition |
| 01/10/2013 | US20130011387 Systems and methods for obtaining immunoglobulin from blood |
| 01/10/2013 | US20130011386 Active protease-resistant antibody fc mutants |
| 01/10/2013 | US20130011385 Transparent bacterial cellulose nanocomposite hydrogels |
| 01/10/2013 | US20130011332 Frozen Compositions and Methods for Piercing a Substrate |
| 01/10/2013 | CA2844532A1 An antibody inducing antigen-specific t cell tolerance and use thereof |
| 01/10/2013 | CA2843854A1 Herpes virus vaccine and methods of use |
| 01/10/2013 | CA2841767A1 Cancer antigen |
| 01/10/2013 | CA2841376A1 N-terminal deleted gp120 immunogens |
| 01/10/2013 | CA2841372A1 Agr2 blocking antibody and use thereof |
| 01/10/2013 | CA2841047A1 Immunogenic compositions and uses thereof |
| 01/10/2013 | CA2841039A1 Multispecific antibodies |
| 01/10/2013 | CA2840989A1 Immunogenic combination compositions and uses thereof |
| 01/10/2013 | CA2840982A1 Human respiratory syncytial virus vaccine |
| 01/10/2013 | CA2840977A1 Liposomes having useful n:p ratio for delivery of rna molecules |
| 01/10/2013 | CA2840965A1 Cationic oil-in-water emulsions |
| 01/10/2013 | CA2840913A1 Oil-in-water emulsions that contain nucleic acids |
| 01/10/2013 | CA2840856A1 Egfr targeted therapy |